Linear-dichroic infrared spectral analysis of Cu(I)-homocysteine complex.
暂无分享,去创建一个
[1] Ivayla N. Pantcheva,et al. Copper(II) complexes of blood pressure active drugs , 2002 .
[2] B. Ivanova,et al. COPPER(II) COMPLEXES OF 1-[O-ALLYLPHENOXY]-3-[ISOPROPYLAMINO]-2-PROPANOL (ALPRENOLOL) , 2001 .
[3] D. Mehandjiev,et al. Complexes of Cu(II) with 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-piperazine (prazosin): synthesis, properties, crystal structure , 2001 .
[4] D. Mehandjiev,et al. Complexes of copper(II) with the β-blocker atenolol , 2000 .
[5] R. D'Agostino,et al. Nonfasting Plasma Total Homocysteine Levels and Stroke Incidence in Elderly Persons: The Framingham Study , 1999, Annals of Internal Medicine.
[6] S. Vollset,et al. Homocysteine and cardiovascular disease. , 1998, Annual review of medicine.
[7] K. Mccully. Homocysteine and vascular disease , 1996, Nature Medicine.
[8] B. Schrader,et al. Reduced IR-LD spectra of substances oriented as nematic solutions , 1995 .
[9] B. Schrader,et al. FT-IR linear dichroic solute spectra of nematic solutions as a tool for IR band assignment , 1993 .
[10] E. Zhecheva,et al. Copper(II) complexes of (1-[isopropylamine]-3-[1-naphthyloxy]-2-propanol) (propranolol) , 1992 .
[11] P. Bontchev,et al. Metallothioneins in spontaneously hypertensive rat liver. , 1992, Japanese journal of medical science & biology.
[12] P. Ueland,et al. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. , 1989, The Journal of laboratory and clinical medicine.
[13] S. Chan,et al. On the nature of cysteine coordination to CuA in cytochrome c oxidase. , 1988, The Journal of biological chemistry.
[14] D. Wilcken,et al. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. , 1976, The Journal of clinical investigation.
[15] F. Dörr,et al. Spectroscopy with Polarized Light , 1966 .
[16] T. Shimanouchi,et al. Infrared spectra of deuterated α-amino acids NH3+CDRCOO , 1959 .